Specific organs
Disease modification in osteoarthritis: are we there yet?
W.M. Oo1, D.J. Hunter2
- Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Australia.
- Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Australia. david.hunter@sydney.edu.au
CER12727
2019 Vol.37, N°5 ,Suppl.120
PI 0135, PF 0140
Specific organs
Free to view
(click on article PDF icon to read the article)
PMID: 31621568 [PubMed]
Received: 02/09/2019
Accepted : 04/09/2019
In Press: 15/10/2019
Published: 15/10/2019
Abstract
A disease-modifying osteoarthritis drug (DMOAD) is a drug that modifies the underlying OA pathophysiology and potentially inhibits the structural damage to prevent or reduce long-term disability with potential symptomatic relief. The focus of this narrative review is on describing the state of the field for disease-modifying pharmacologic agents that are in late-stage development-specifically phase 2/3.
